𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study

✍ Scribed by Fernández-Rodríguez, Conrado M.; Morillas, Rosa María; Masnou, Helena; Navarro, José María; Bárcena, Rafael; González, José Manuel; Martín-Martín, Leticia; Poyato, Antonio; Miquel-Planas, Mireia; Jorquera, Francisco; Casanovas, Teresa; Salmerón, Javier; Calleja, José Luis; Solà, Ricard; Alonso, Sonia; Planas, Ramón; Romero-Gomez, Manuel

Book ID
122187525
Publisher
Elsevier Science
Year
2014
Tongue
Spanish
Weight
852 KB
Volume
37
Category
Article
ISSN
0210-5705

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of high-dose peginterferon alfa-2
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial
✍ Stuart K. Roberts; Martin D. Weltman; Darrell H. G. Crawford; Geoffrey W. McCaug 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 2 views

This study tested the hypothesis that high-dose peginterferon alfa-2a (PEG-IFNalpha-2a) for the first 12 weeks would increase early and sustained virological response (SVR) rates in patients with chronic hepatitis C genotype 1. Eight hundred ninety-six patients were randomized 1:1 to 360 microg (n =

A randomized, prospective trial of ribav
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3
✍ Peter Ferenci; Harald Brunner; Hermann Laferl; Thomas-Matthias Scherzer; Andreas 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB

öschenberger, 10 for the Austrian Hepatitis Study Group We compared the efficacy and tolerability of 24 weeks of treatment with ribavirin 800 mg/day (group A) or 400 mg/day (group B) plus peginterferon alfa-2a 180 g/week in treatment-naive patients infected with hepatitis C virus (HCV) genotype 2 o